This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation. This may include inher…

Chronic Granulomatous Disease (CGD)X-Linked Severe Combined Immune Deficiency (XSCID)Leukocyte Adhesion Deficiency 1 (LAD)+1 more

~Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT00128973

Phase 3

A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II (LAD II)

The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, T…

Leukocyte Adhesion Deficiency

~Estimated

~$10 – $8,750

AUG TherapeuticsNCT05462587

Phase 3

A Phase 3, Open-Label, Extension Study to Assess the Long-term Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II (LAD II)

The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).

Leukocyte Adhesion Deficiency

~Estimated

~$10 – $8,750

AUG TherapeuticsNCT05754450